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Abstract: Current therapeutic options for obesity often require pharmacological intervention with
dietary restrictions. Obesity is associated with underlying inflammation due to increased tissue
macrophage infiltration, and recent evidence shows that inflammation can drive obesity, creating
a feed forward mechanism. Therefore, targeting obesity-induced macrophage infiltration may be
an effective way of treating obesity. Here, we developed cargo-less liposomes (UTS-001) using
1,2-dioleoyl-sn-glycero-3-phosphocholine, DOPC (synthetic phosphatidylcholine) as a single-agent
to manage weight gain and related glucose disorders due to high fat diet (HFD) consumption
in mice. UTS-001 displayed potent immunomodulatory properties, including reducing resident
macrophage number in both fat and liver, downregulating liver markers involved in gluconeogenesis,
and increasing marker involved in thermogenesis. As a result, UTS-001 significantly enhanced
systemic glucose tolerance in vivo and insulin-stimulated cellular glucose uptake in vitro, as well
as reducing fat accumulation upon ad libitum HFD consumption in mice. UTS-001 targets tissue
residence macrophages to suppress tissue inflammation during HFD-induced obesity, resulting in
improved weight control and glucose metabolism. Thus, UTS-001 represents a promising therapeutic
strategy for body weight management and glycaemic control.
Keywords: inflammation; obesity; 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) liposomes;
high fat diet
1. Introduction
A third of the global population is affected by obesity and the population of obese people has
been doubled since the 1980s [1]. Obesity is a complex multifactorial disease characterized by excess
fat deposits causing dyslipidaemia and is strongly associated with insulin resistance leading to glucose
intolerance and eventually type 2 diabetes [2,3]. Current obesity management depends on lifestyle
modification alone or in combination with either pharmacological treatment or bariatric surgery
according to the severity of obesity and co-morbidities [4]. Common lifestyle modifications achieve
little effects in weight management due to low adherence [5]. Anti-obesity drugs are associated with
serious side effects (psycho-stimulatory, depression, addiction, gastrointestinal effects) [6–9]. Bariatric
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surgery is the only effective therapy used in patients who are morbidly obese, but this carries several
side effects such as osteoporosis and malnutrition in the long term [10]. Thus, there is a need for
developing new effective therapeutics with fewer side effects to manage body weight and related
metabolic disorders.
Obesity is exemplified by chronic systemic low-grade inflammation, marked by the recruitment
of monocytes into metabolic organs, which then form resident macrophages, such as adipose
tissue macrophages (ATM) or Kupffer cells in the liver [11]. These resident macrophages release
pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) [12],
which act locally and systemically to impair insulin sensitivity and related glucose uptake. TNF-α also
causes pre-adipocytes to differentiate into macrophage-like cells that produce more pro-inflammatory
cytokines [13]. Thus, reducing the recruitment of macrophages has been shown to protect mice from
obesity-induced insulin resistance [14]. Moreover, inhibiting pro-inflammatory cytokine release
has been shown to increase lipolysis, resulting in fat loss and improved insulin sensitivity in
obese mice [15,16]. However anti-TNF-α treatment failed in the clinical trial, suggesting a new
anti-inflammatory approach needs to target macrophages instead of individual pro-inflammatory
cytokines to effectively manage body weight and metabolic disorders in obesity.
Recent studies have demonstrated the efficacy of a mixture of natural phosphatidylcholines
(PCs) in diet-induced obesity and hyperlipidemia in vivo [17,18], with another two studies reporting
antidiabetic effects and reducing liver mitochondrial injury following dilinoleoylphosphatidylcholine
(DLPC) administration [19,20]. Furthermore, PCs in the form of liposome are currently used in several
registered formulations on the market, but no studies to date have investigated the therapeutic effect
of the cargo-less liposomal formulation of PCs.
Natural phospholipids are available as a heterogeneous mixture of PCs with different fatty acyl
chains. Due to the presence of multiple unsaturated fatty acids, natural PCs are generally unstable [21].
In the present study, a pure, synthetic PC, 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) has been
formulated as liposomes without any active therapeutic loaded inside (cargo less liposome-UTS-001).
In our previous studies, UTS-001 significantly reduced IL-6 release following TNF-α stimulation
in airway epithelial cells in vitro and reduced airway inflammation in a mouse model of allergic
asthma [22]. Similarly, metabolic disorders are caused by systemic low-grade inflammation with
pro-inflammatory cytokines playing a significant role in disease development. The anti-inflammatory
effect of UTS-001 may target resident macrophages in the obese to exert therapeutic efficacy by reducing
fat accumulation and improving glucose disorders.
Therefore, in the current study, mice on a high-fat diet (HFD) were intraperitoneally injected with
the UTS-001 to examine the efficacy of this liposomal formulation on reducing resident macrophage,
related inflammatory parameters, and fat accumulation.
2. Results
2.1. In Vivo Studies
2.1.1. Anthropometric and Metabolic Parameters
To model obesity, mice were fed a HFD (20 KJ/g, 43% fat) for 6 weeks. Control mice were fed
standard rodent chow (12 KJ/g, 14% fat). From the 7th week, 2 doses of UTS-001 (0.6 mg and 6 mg)
were administered once daily to HFD-fed mice for four weeks while the maintenance diet remained
unchanged. As shown in Table 1, at week 0, the mean body weight of HFD-fed mice was the same as
the chow-fed mice. At the endpoint, no significant difference was observed in body weight among
chow-fed mice regardless of UTS-001 dose, suggesting no toxicity. Interestingly, the final body weight
of the HFD-UTS-001 (6 mg) group was 8.9% lower compared to that of the HFD-PBS group (p < 0.05).
The final body weight of HFD fed mice receiving UTS-001 (0.6 mg) did not show any significant change
compared to HFD-PBS mice. There was a significant increase (p < 0.0001) in calorie intake of HFD-fed
groups compared to Chow-fed groups. Furthermore, the HFD mice treated with UTS-001 (0.6 mg) had
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a significant increase (p < 0.05) in calorie intake compared to HFD-PBS mice. this effect was not seen in
UTS-001 (6 mg) treated HFD mice.
Table 1. Effects on anthropometric parameters of mice with HFD and UTS-001 treatment.







Body weight at 0 week (g) 19.9 ± 0.3 20.3 ± 0.1 19.8 ± 0.3 19.5 ± 0.3 20.1 ± 0.3 19.9 ± 0.3
Body weight at 10 weeks (g) 28.7 ± 0.5 29.5 ± 0.5 28.1 ± 0.4 37.1 ± 0.8 **** 38.3 ± 1.5 **** 33.8 ± 1.2 ****,##
Twenty-four calorie intake
(kJ/mouse/day) 36.18 ± 2.18 28.05 ± 0.69 37.45 ± 3.25 238.4 ± 33.13 ****
318.53 ± 37.27
****# 261.41 ± 30.06 ****
Kidney (g) 0.192 ± 0.005 0.193 ± 0.012 0.181 ± 0.009 0.215 ± 0.007 * 0.213 ± 0.014 0.213 ± 0.009
% 0.690 ± 0.018 0.690 ± 0.018 0.670 ± 0.031 0.603 ± 0.027 * 0.592 ± 0.021 * 0.642 ± 0.019
Liver (g) 1.18 ± 0.005 1.27 ± 0.03 1.22 ± 0.04 1.56 ± 0.07 **** 1.58 ± 0.07 ** 1.400 ± 0.040 **,#
% 4.23 ± 0.15 0.683 ± 0.037 4.51 ± 0.12 4.30 ± 0.12 4.46 ± 0.31 4.23 ± 0.11
Heart (g) 0.143 ± 0.005 0.146 ± 0.007 0.139 ± 0.008 0.159 ± 0.006 0.150 ± 0.008 0.149 ± 0.012
% 0.511 ± 0.012 0.514 ± 0.018 0.517 ± 0.030 0.433 ± 0.015 * 0.422 ± 0.019 ** 0.433 ± 0.018 *
Spleen (g) 0.096 ± 0.012 0.087 ± 0.007 0.085 ± 0.014 0.110 ± 0.007 0.096 ± 0.015 0.105 ± 0.011
% 0.343 ± 0.041 0.308 ± 0.021 0.312 ± 0.042 0.298 ± 0.014 0.259 ± 0.029 0.305 ± 0.020
Rp fat (g) 0.091 ± 0.010 0.107 ± 0.012 0.077 ± 0.013 0.680 ± 0.057 **** 0.767 ± 0.111 **** 0.405 ± 0.070 ***,##
% 0.324 ± 0.033 0.380 ± 0.040 0.284 ± 0.046 1.86 ± 0.12 **** 2.17 ± 0.36 **** 1.19 ± 0.18 ****,##
Testicular fat (g) 0.381 ± 0.017 0.444 ± 0.044 0.312 ± 0.034 1.81 ± 0.13 **** 1.93 ± 0.15 **** 1.04 ± 0.16 ****,####
% 1.37 ± 0.06 1.57 ± 0.15 1.16 ± 0.12 4.95 ± 0.29 **** 5.36 ± 0.30 **** 3.05 ± 0.40 ****,####
Data are expressed as mean ± S.E.M. and were analysed using two-way ANOVA, followed by post hoc Fisher’s LSD
tests. n = 6–12. * p < 0.05 vs. Chow-PBS; ** p < 0.01 vs. Chow-PBS; *** p < 0.001 vs. Chow-PBS; **** p < 0.0001
vs. Chow-PBS, # p < 0.05 vs. HFD-PBS; ## p < 0.01 vs. HFD-PBS; ### p < 0.001 vs. HFD-PBS; #### p < 0.0001
vs. HFD-PBS.
HFD-PBS group demonstrated significantly greater retroperitoneal fat content, liver weight and
testicular fat levels compared to the Chow-PBS group (p < 0.0001 for all, Table 1). Furthermore,
there was no significant difference in fat mass between chow mice receiving UTS-001 or PBS while a
significant decrease in liver weight (p < 0.05), retroperitoneal (Rp) fat (p < 0.001), and testicular fat mass
(p < 0.0001) were observed between HFD-UTS-001 (6 mg) group and HFD-PBS group. No significance
in liver weight% was observed between the groups. With respect to Rp fat % and testicular fat %,
UTS-001 (6 mg) treatment significantly reduced these parameters when compared to HFD-PBS group
(p < 0.01 for Rp fat % and p < 0.0001 for Testicular fat %). Among all the other organs (Tibia, heart,
spleen) only heart weight % was significantly reduced in all HFD-fed groups compared to Chow-PBS.
As demonstrated in Table 2, serum triglycerides (TG) level in HFD fed mice were significantly
higher compared to the Chow-PBS group (HFD-PBS, p < 0.05) which were not affected by UTS-001
(6 mg) treatment (Table 2). Serum free fatty acid (FFA) level was 15% higher in HFD-PBS group, which
was normalized in HFD-UTS-001 (6 mg), although without statistical significance (Table 2).
Table 2. Lipid and glucose profiles in mice with HFD and UTS-001 treatment.







Serum TG (mg/mL) 0.94 ± 0.032 1.15 ± 0.05 1.06 ± 0.047 1.12 ± 0.047* 1.21 ± 0.062 ** 1.19 ± 0.062 ***
Serum FFA (nM) 4.82 ± 0.21 4.74 ± 0.27 4.9 ± 0.25 5.49 ± 0.35 5.95 ± 0.48 4.8 ± 0.15
Liver Oil Red O staining
(OD/mg of tissue)
0.0057 ±




**** 0.019 ± 0.00346 ****
Glucose (mM) 12.8 ± 1.2 12.9 ± 1.4 14.8 ± 0.3 17.5 ± 1.2 ** 19.15 ± 0.9 *** 18.1 ± 1.1 **
Serum insulin (ng/mL) 0.399 ± 0.02 0.40 ± 0.04 0.409 ± 0.04 0.412 ± 0.02 0.399 ± 0.03 0.415 ± 0.03
HOMA-IR 0.22 ± 0.02 0.24 ± 0.03 0.27 ± 0.01 0.34 ± 0.02 **** 0.34 ± 0.01 *** 0.32 ± 0.02 ***
Data are expressed as mean ± S.E.M. and were analysed using two-way ANOVA, followed by post hoc Fisher’s LSD
tests. n = 7–12. * p < 0.05 vs. Chow-PBS; ** p < 0.01 vs. Chow-PBS; *** p < 0.001 vs. Chow-PBS; **** p < 0.0001
vs. Chow-PBS.
Fasting blood glucose concentrations in HFD-PBS group were significantly increased (p < 0.01 vs.
Chow-PBS, Table 2), which was not changed by UTS-001 (0.6 mg and 6 mg) treatment. There was no
significant difference in insulin levels among any groups. Homeostatic Model Assessment of Insulin
Resistance (HOMA-IR), an indicator of insulin resistance, was significantly increased (p < 0.0001) in
HFD-PBS group compared to the Chow-PBS group, which was not changed by UTS-001 treatment.
As shown in Figure 1a, during intraperitoneal glucose tolerance test (IPGTT) blood glucose level was
significantly increased in the HFD-PBS group at 15, 30, 60 and 90 min as expected (p < 0.0001 for 30,
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60, 90 min; p < 0.05 for 15 min and p < 0.01 for 0 min vs. Chow-PBS). HFD mice receiving UTS-001
(6 mg) treatment had significantly lowered blood glucose levels in comparison to the HFD-PBS group
(p < 0.001 for 60 and 90 min, p < 0.01 for 15 min). The area under the curve (AUC) was significantly
higher in the HFD-PBS groups (p < 0.0001 vs. Chow-PBS). Interestingly, in the HFD-UTS-001 (6 mg)
group, AUC has been decreased significantly (p < 0.0001 vs. HFD-PBS, Figure 1b), suggesting improved
glucose tolerance by UTS-001 (6 mg) treatment.
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 4 of 21 
 
UTS-001 (6 mg) group, AUC has been decreased significantly (p < 0.0001 vs. HFD-PBS, Figure 1b), 
suggesting improved glucose tolerance by UTS-001 (6 mg) treatment. 











Serum TG (mg/mL) 0.94 ± 0.032  1.15 ± 0.05 1.06 ± 0.047 1.12 ± 0.047* 1.21 ± 0.062 ** 1.19 ± 0.062 *** 
Serum FFA (nM) 4.82 ± 0.21 4.74 ± 0.27 4.9 ± 0.25 5.49 ± 0.35 5.95 ± 0.48 4.8 ± 0.15 
Liver Oil Red O staining 
(OD/mg of tissue) 
0.0057 ± 
0.00032 
0.0066 ± 0.00059 0.00501 ± 0.00031 
0.01898 ± 
0.00321 *** 
0.02489 ± 0.0016 
**** 
0.019 ± 0.00346 
**** 
Glucose (mM) 12.8 ± 1.2 12.9 ± 1.4 14.8 ± 0.3 17.5 ± 1.2 ** 19.15 ± 0.9 *** 18.1 ± 1.1 ** 
Serum insulin (ng/mL) 0.399 ± 0.02 0.40 ± 0.04 0.409 ± 0.04 0.412 ± 0.02 0.399 ± 0.03 0.415 ± 0.03 
HOMA-IR 0.22 ± 0.02 0.24 ± 0.03 0.27 ± 0.01 
0.34 ± 0.02 
**** 
0.34 ± 0.01 *** 0.32 ± 0.02 *** 
Data are expressed as mean ± S.E.M. and were analysed using two-way ANOVA, followed by post 
hoc Fisher’s LSD tests. n = 7–12. * p < 0.05 vs. Chow-PBS; ** p < 0.01 vs. Chow-PBS; *** p < 0.001 vs. 
Chow-PBS; **** p < 0.0001 vs. Chow-PBS. 
 
Figure 1. (a) An intraperitoneal glucose tolerance test (IPGTT, glucose 2 g/kg) after 4 weeks of 
treatment. (b) Area under the curve (AUC) of the IPGTT in (a). Data are expressed as mean ± S.E.M, 
n = 7–12. Data were analysed using two-way ANOVA followed by post hoc Fischer’s LSD tests. In (a), 
** p < 0.01, Chow-PBS vs. HFD-PBS at o min; * p < 0.05, Chow-PBS vs. HFD-PBS at 15 min; **** p < 
0.0001, Chow-PBS vs. HFD-PBS at 30, 60, 90 min, ### p < 0.001, HFD-PBS vs. HFD-UTS-001 at 60, 90 
min and ## p < 0.01, HFD-PBS vs. HFD-UTS-001 at 30 min. in (b) **** p < 0.0001 vs. Chow-PBS; #### p 
< 0.0001 vs. HFD-PBS group. 
Thus, four weeks of UTS-001 (6 mg) treatment reduced body weight gain and fat mass with no 
effect on plasma TG in HFD-fed mice. Although insulin resistance was not improved, systemic 
glucose metabolism has been significantly improved upon high glucose challenge. To investigate if 
the components of UTS-001 (DOPC and cholesterol mixture) affect these parameters, a second cohort 
of animals was used. There was no significant weight change, nor significant improvement in glucose 
tolerance following treatment with non-liposomal DOPC and cholesterol mixture, whilst a small but 
significant reduction was observed with DOPC liposomes (Supplementary Figure A1), the effect of 
which was not as potent as UTS-001. 
2.1.2. Inflammatory Markers 
In the liver, HFD consumption alone significantly up-regulated TNF-α and toll-like receptor-4 
(TLR4) mRNA expression (TNF-α, p < 0.01 HFD-PBS vs. Chow-PBS, Figure 2a; TLR4, p < 0.05 HFD-
PBS vs. Chow-PBS, Figure 2d). No significant changes in mRNA expression of liver IL-6 (Figure 2b) 
and monocyte chemoattractant protein-1 (MCP-1) (Figure 2c) have been observed among the groups. 
Interleukin 1-beta (IL-1β) mRNA expression was decreased in UTS-001 treated Chow-fed mice (p < 
0.01 for 0.6 mg and p < 0.05 for 6 mg vs. Chow-PBS group) (Figure 2e). 
1. (a) An intraperitoneal g ucose tolerance test (IPGTT, glucose 2 g/kg) after 4 weeks of treatment.
(b) Ar a under the curv (AUC) of the IPGTT in (a). Data are expressed as mean ± S.E.M, n = 7–12.
Data were nalysed using two-way ANOVA followed by p st hoc Fischer’s LSD tests. In (a), ** p < 0.01,
Chow-PBS vs. HFD-PBS at o min; * p < 0.05, Chow-PBS vs. HFD-PBS at 15 min; **** p < 0.0001,
Chow-PBS vs. HFD-PBS at 30, 60, 90 min, ### p < 0.001, HFD-PBS vs. HFD-UTS-001 at 60, 90 min and
## p < 0.01, HFD-PBS vs. HFD-UTS-001 at 30 min. in (b) **** p < 0.0001 vs. Chow-PBS; #### p < 0.0001
vs. HFD-PBS group.
Thus, four weeks of UTS-001 (6 mg) treatment reduced body weight gain and fat mass with
no effect on plasma TG in HFD-fed mice. Although insulin resistance was not improved, systemic
glucose metabolism has been significantly improved upon high glucose challenge. To investigate if the
components of UTS-001 (DOPC and cholesterol mixture) affect these parameters, a second cohort of
animals was used. There was no significant weight change, nor significant improvement in glucose
tolerance following treatment with non-liposomal DOPC and cholesterol mixture, whilst a small but
significant reduction was observed with DOPC liposo es (Supple entary Figure S1), the effect of
which was not as potent as UTS-001.
2.1.2. Inflammatory Markers
In the liver, HFD consumption alone significantly up-regulated TNF-α and toll-like receptor-4
(TLR4) mRNA expression (TNF-α, p < 0.01 HFD-PBS vs. Chow-PBS, Figure 2a; TLR4, p < 0.05 HFD-PBS
vs. Chow-PBS, Figure 2d). No significant changes in mRNA expression of liver IL-6 (Figure 2b)
and monocyte chemoattractant protein-1 (MCP-1) (Figure 2c) have been observed among the groups.
Interleukin 1-beta (IL-1β) mRNA expression was decreased in UTS-001 treated Chow-fed mice (p < 0.01
for 0.6 mg and p < 0.05 for 6 mg vs. Chow-PBS group) (Figure 2e).
Macrophages number in the liver was assessed using F4/80 and CD68 staining. Liver F4/80
positive cells have been increased (p < 0.05) in the HFD-PBS group (Figure 2f), which has been
markedly decreased in the HFD-UTS-001 (6 mg) group (p < 0.01 vs. HFD-PBS). CD68 positive cells
were also markedly increased in HFD-PBS group compared to Chow-PBS group (p < 0.01), which was
significantly decreased in the HFD-UTS-001 (6 mg) group (p < 0.05 vs. HFD-PBS, Figure 2g).
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IL-1β. Percentage of macrophage number as identified by (f) F4/80 and (g) CD68 immunohistochemistry 
staining and (h) and (i) respective representative images were taken at 10× magnification. Positive 
staining indicated by arrows in h and i. Data are represented as mean ± S.E.M and were analysed 
using two-way ANOVA followed by post hoc Fischer’s LSD test, n = 5–9. * p < 0.05 vs. Chow-PBS; ** 
p < 0.01 vs. Chow-PBS; # p < 0.05 vs. HFD-PBS; ## p < 0.01 vs. HFD-PBS. 
In the fat tissue, no significant changes in TNF-α (Figure 3a) and IL-6 (Figure 3b) mRNA expression 
were observed among all groups. Fat MCP-1 (Figure 3c) mRNA expression was significantly increased 
in HFD-PBS group compared to Chow-PBS (p < 0.05), which was lower in UTS-001 treated groups 
albeit with no statistical significance. Fat IL-1β mRNA expression was not significantly different 
among all groups, although the levels were reduced by more than 50% in HFD-fed mice after UTS-
001 treatment (Figure 3d). F4/80 positive cell number in fat tissue in the HFD-PBS group (Figure 3b) 
was significantly higher than the Chow-PBS (p < 0.05). In the HFD-UTS-001 (6 mg) group, F4/80 
positive cells were decreased by nearly 50% but this change was not statistically significant (p = 0.09 
vs. HFD-PBS). 
Figure 2. Liver mRNA expression of inflammatory markers (a) TNF-α, (b) IL-6, (c) MCP-1, (d)
TLR-4, (e) IL-1β. Percentage of macrophage number as identified by (f) F4/80 and (g) CD68
immunohistochemistry staining and (h) and (i) respective representative images were taken at 10×
magnification. Positive staining indicated by arrows in h and i. Data are represented as mean ± S.E.M
and were analysed using two- ay ANOVA followed by post hoc Fischer’s LSD test, n = 5–9. * p < 0.05
vs. Chow-PBS; ** p < 0.01 vs. Chow-PBS; # p < 0.05 vs. HFD-PBS; ## p < 0.01 vs. HFD-PBS.
In the fat tissue, no significant changes in T F-α (Figure 3a) and IL-6 (Figure 3b) ex ression
ere observed a ong a l groups. Fat MCP-1 (Figure 3c) mRNA expre sion was significantly increased
in compared to Chow-PBS (p < 0.05), whic was lower in UTS-001 treated groups albeit
with no statistical significance. F t IL-1β mRNA expression was not significantly different among all
groups, although the levels were reduced by more than 50% in HFD-fed mice after UTS-001 tr atment
(Figure 3d). F4/80 positive cell number in fat tissue in the HFD-PBS group ( igure 3b) was significantly
higher than the C ow-PBS (p < 0.05). In the HFD-UTS-001 (6 mg) group, F4/80 positive cells were
decreased by n arly 50% but this change was no statistically significant (p = 0.09 vs. HFD-PBS).
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Figure 3. Fat mRNA expression of (a) TNF-α, (b) IL-6, (c) MCP-1, (d) IL-1β and (e) Percentage of 
macrophage number in the fat as identified by F4/80 immunohistochemistry and (f) Respective 
representative images for the stain taken at 10× magnification. Positive staining indicated by arrows 
in figure f. Data are represented as mean ± S.E.M and were analysed using two-way ANOVA followed 
by post hoc Fisher’s LSD test, n = 6–9. * p < 0.05 vs. Chow-PBS. 
Figure 3. Fat mRNA expression of (a) TNF-α, (b) IL-6, (c) MCP-1, (d) IL-1β and (e) Percentage
of macrophage number in the fat as identified by F4/80 immunohistochemistry and (f) Respective
representative images for the stain t ken at 10×magnification. Positive staining indicated by arrows in
figure f. Data are represented as mean ± S.E.M and were analysed using two-way ANOVA followed by
post hoc Fisher’s LSD test, n = 6–9. * p < 0.05 vs. Chow-PBS.
2.1.3. mRNA Expression of Metabolic Markers in Livertitle
As shown in Figure 4, a significant increase in mRNA expression of glucose metabolic
markers, including forkhead box protein O1 (FOXO1) (p < 0.001, 4a), glucose transporter 2 (GLUT2)
(p < 0.001, 4b), peroxisome proliferator-activated receptor (PPAR)γ (p < 0.0001, 4c), and peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) (p < 0.05, 4d) levels are seen in the
liver of the HFD-PBS group compared to the Chow-PBS group. A decrease in the expression of PPARγ
(p < 0.05 vs. HFD-PBS) in the HFD-UTS-001 (6 mg) group was noted. Furthermore, treatment with
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UTS-001 (6 mg) in the HFD group resulted in a reduction of FOXO-1 by 19% (p = 0.06) and GLUT2 by
15% compared to HFD-PBS, which was not statistically significant.
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 21 
 
2.1.3. mRNA Expression of Metabolic Markers in Liver 
As shown in Figure 4, a significant increase in mRNA expression of glucose metabolic markers, 
including forkhead box protein O1 (FOXO1) (p < 0.001, 4a), glucose transporter 2 (GLUT2) (p < 0.001, 
4b), peroxisome proliferator-activated receptor (PPAR)γ (p < 0.0001, 4c), and peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α) (p < 0.05, 4d) levels are seen in the liver of 
the HFD-PBS group compared to the Chow-PBS group. A decrease in the expression of PPARγ (p < 
0.05 vs. HFD-PBS) in the HFD-UTS-001 (6 mg) group was noted. Furthermore, treatment with UTS-
001 (6 mg) in the HFD group resulted in a reduction of FOXO-1 by 19% (p = 0.06) and GLUT2 by 15% 
compared to HFD-PBS, which was not statistically significant. 
 Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 9 of 21 
 
 
Figure 4. mRNA expression of liver glucose and lipids markers (a) FOXO-1, (b) GLUT-2, (c) PPARγ, (d) 
PGC-1α, (e) SREBP-1c, (f) FASN, (g) ATGL, (h) CPT-1a. Results are expressed as mean ± S.E.M, n = 7–9. 
Data were analyzed by two-way ANOVA followed by post hoc Fischer’s test. * p < 0.05 vs. Chow-PBS; 
*** p < 0.001 vs. Chow-PBS; **** p < 0.0001 vs. Chow-PBS, p = 0.06 vs. HFD-PBS, # p < 0.0001 vs. HFD-PBS. 
No significant difference was observed in liver lipid metabolic markers, including Sterol regulatory 
element-binding protein 1 (SREBP-1c), fatty acid synthase (FASN), adipose triglyceride lipase (ATGL), 
and carnitine palmitoyltransferase 1a (CPT-1a) mRNA expression among all the groups. 
2.1.4. mRNA Expression of Metabolic Markers in the Fat 
In the fat tissue, a significant increase in mRNA expression of CPT-1a was observed in the HFD-
PBS group compared to the Chow-PBS group (p < 0.01 Figure 5a), which was normalised by UTS-001 
(6 mg) treatment (p < 0.01, HFD-UTS-001 (6 mg) vs. HFD-PBS). Furthermore, no significant difference 
in fat ATGL mRNA expression was observed, although the level was more than tripled in the HFD-
UTS-001 (6 mg) group compared with the HFD-PBS group (Figure 5b) and no significant difference 
in PPARγ mRNA expression was observed among all groups (5c). 
 
Figure 4. mRNA expression of liver glucose and lipids markers (a) FOXO-1, (b) GLUT-2, (c) PPARγ,
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vs. HFD-PBS.
No significant difference was observed in liver lipid metabolic markers, including Sterol regulatory
element-binding protein 1 (SREBP-1c), fatty acid synthase (FASN), adipose triglyceride lipase (ATGL),
and carnitine palmitoyltransferase 1a (CPT-1a) mRNA expression among all the groups.
Int. J. Mol. Sci. 2020, 21, 7640 9 of 20
2.1.4. mRNA Expression of Metabolic Markers in the Fat
In the fat tissue, a significant increase in mRNA expression of CPT-1a was observed in the
HFD-PBS group compared to the Chow-PBS group (p < 0.01 Figure 5a), which was normalised by
UTS-001 (6 mg) treatment (p < 0.01, HFD-UTS-001 (6 mg) vs. HFD-PBS). Furthermore, no significant
difference in fat ATGL mRNA expression was observed, although the level was more than tripled in
the HFD-UTS-001 (6 mg) group compared with the HFD-PBS group (Figure 5b) and no significant
difference in PPARγ mRNA expression was observed among all groups (5c).
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Figure 5. mRNA expression of (a) CPT-1a; (b) ATGL; (c) PPARγ in the fat. Results are expressed as
mean ± S.E.M, n = 7–9. Data were analyzed by two-way ANOVA followed by post hoc Fisher’s test.
** p < 0.01 vs. Chow-PBS; ## p < 0.01 vs. HFD-PBS.
2.1.5. mRNA Expression of Thermogenesis Markers in Brown Fat
Chow-fed mice receiving UTS-001 (0.6 mg) had shown a significant rise (p < 0.05) in Uncoupling
protein-1 (UCP-1) levels compared to chow-PBS mice. UCP-1 mRNA expression level was also
significantly increased in HFD fed mice treated with UTS-001 (0.6 mg) (p < 0.01 vs. chow-PBS and
p < 0.01 vs. HFD-PBS group) and UTS-001 (6 mg) (p < 0.05 vs. chow-PBS and p < 0.05 vs. HFD-PBS
groups) (Figure 6a). Moreover, there were no changes in UCP-3 levels among the groups (Figure 6b).
2.2. Effect of UTS-001 on Uptake of 2-(N-(7-Nitrobenz-2-oxa-1, 3-Diazol-4-yl) Amino)-2 Deoxyglucose
(2-NBDG), Number and Diameter of Adipocytes In Vitro
We performed a glucose uptake assay in differentiated mature adipocytes from the 3T3L cell
line. As shown in Figure 7a, the fluorescently labeled glucose analogue, 2-NBDG was significantly
increased by the first line anti-diabetic drug metformin (p < 0.01) as a positive control. All the
concentrations of UTS-001 (p < 0.01 for 3.375 mg/mL, p < 0.001 for 0.375 and 2.25 mg/mL, p < 0.0001
for 1.125 mg/mL of lipids) have achieved similar effects as metformin to increase glucose uptake in
matured adipocytes. As shown in Figure 7b,c, no significant changes were observed in the number
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and diameter of adipocytes among groups after treatment with UTS-001, although there was a trend of
decreasing adipocyte diameter with the increase in UTS-001 dose.
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3. Discussion
Obesity is a low-grade systemic inflammatory disease induced by increased and overactivation of
tissue resident macrophages, hence targeting residence macrophages may assist weight management
and related metabolic disorders. In the current study, we have developed a liposomal formulation of
DOPC (UTS-001) that is able to reduce residence macrophage number and inflammation. UTS-001(6 mg)
treatment protected mice against weight gain and fat accumulation with ad libitum consumption of a
HFD. Furthermore, UTS-001(6 mg) treatment decreased glucose intolerance in obese mice representing
pre-diabetes conditions in humans [23]. Furthermore, an increase in thermogenesis marker, reflected
by UCP-1 levels in brown fat, may serve as an additional mechanism behind the fat loss effect.
HFD consumption resulted in an increase in body weight, fat mass, and liver weight consistent
with our previous study using the same model [24]. Daily injection of UTS-001 (6 mg) can limit such
obesogenic effects without affecting daily caloric intake. Clinical studies have demonstrated that only
a 5–10% weight loss can result in a significant improvement in obesity-related metabolic disorders [25].
In the current study, 8.9% of weight loss was achieved following four weeks of daily administration of
UTS-001, resulting in significantly improved systemic glucose uptake during IPGTT, the gold standard
method to diagnose diabetes. This effect was only apparent in the high dose (6 mg) group. Glucose
uptake improvement by UTS-001 was further confirmed in the in vitro studies where we observed an
increase in the insulin-dependent uptake of 2-NBDG in mature adipocytes. This is in line with the
efficacy of Caulerpa lentillifera extract as an antidiabetic drug shown by Sharma et al. [26]. Adipocytes
play vital roles in regulating energy balance and glucose homeostasis, where enlarged adipocyte size
is associated with insulin resistance [27]. Although the HOMA results did not suggest a systemic
improvement in insulin resistance, upon a high level of glucose challenge, tissue glucose uptake was
improved. Glucose homeostasis is regulated by insulin/AKT and AMPK pathways in insulin-response
tissues, which promotes GLUT4 translocation to the cell membrane for postprandial glucose uptake.
Improved systemic glucose clearance during IPGTT in this study could be through the modulation
of this insulin/AKT and AMPK pathways when insulin secretion is increased in response to a high
level of circulating glucose challenge [28–30] indirectly supported by our in vitro study. Furthermore,
improved glucose uptake in HFD-fed mice in this study could also be explained by the fact that
phospholipase A2 (PLA2) is normally elevated in inflamed organs [31]. The breakdown of DOPC
liposomes by PLA2 is known to release oleic acid and unsaturated 18:1 lysophosphatidylcholine
(LPC) [32]. This LPC species acts via GPR119, a key receptor that regulates the secretion of insulin
from β cells of pancreatic islets [33], which may explain the reduced blood glucose level following
IPGTT. The impact of UTS-001 on β cell function requires further investigation, which is beyond the
scope of this study. Together, the results from our in vivo and in vitro studies support a novel role for
UTS-001 in improving glucose uptake in mice.
During obesity, there is an increased number of macrophages infiltration in adipose tissue
and liver [34,35]. Increased Lipid influx and accumulation in those organs cause the activation
of Kupffer cells (liver resident macrophages) and monocyte-derived macrophages. Moreover,
chronic hepatic inflammation leads to fatty liver disease and cirrhosis [35]. In the current study,
macrophages were increased in both liver and fat tissue of HFD-PBS group, which were decreased
with reduced inflammatory responses by UTS-001 treatment in both organs. TNF-α produced by
tissue-resident macrophages causes metabolic syndrome and insulin resistance [36,37]. In humans,
addressing this pathophysiological mechanism has been challenging. Corticosteroids, the most effective
anti-inflammatory medications, cause obesity and diabetes at high doses (via gluconeogenesis and
thereafter fat re-distribution), and the recent ASCEND (A Study of Cardiovascular Events in Diabetes)
trial of the non-steroidal anti-inflammatory drug (NSAID), aspirin in diabetes found the risk profile
to outweigh any benefit [38]. Anti-TNF therapies used clinically for immune/autoimmune diseases
have failed the clinical trial to manage body weight in obese people [39], suggesting that targeting
TNF alone is not effective. In the current study, we observed broader efficacy by UTS-001 treatment
which is evident by reduced fat mass, body weight and improved glucose metabolism in the face
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of reduced tissue macrophage numbers and inflammatory response consistent with the hypothesis
of the effectiveness of targeting macrophages to improve obesity-related metabolic disorder [40].
MCP-1 is a key chemokine involved in the infiltration of monocytes and elevated levels of this
chemokine is witnessed in white adipose tissue which is consistent with the findings in the current
study [41]. However, there is no change after UTS-001 (6 mg) treatment indicating that a decrease in
monocyte recruitment may not be the mechanism through which UTS-001 (6 mg) reduced macrophage
number. The migration of macrophages out of the resident tissue after engulfing UTS-001 may be
increased, which requires further investigation to confirm. In chow-fed mice, there was an apparent
(non-significant) increase in the number of adipose tissue macrophages, whereas significantly reduced
HFD-induced macrophage accumulation. In the liver, there was no such increase of macrophages
by UTS-001 in chow fed animals, therefore the apparent increase in adipose tissue is not a general
effect of UTS-001. We are not certain of the exact cause of this increase, but as UTS-001 is lipid based
it could be that adipocytes partially recognise UTS-001 as a lipid and begin normal homeostatic
mechanisms, i.e., recruit macrophages to adipose tissue. This dual response of lipids is common, for
example, PGE2 treatment of cells results in the induction of inflammatory mediators [42] whereas
PGE2 production from macrophages is an important anti-inflammatory signal to inhibit the production
of pro-inflammatory cytokines [43].
Glucose intolerance is considered to be a high risk of developing type 2 diabetes [44]. FOXO-1 plays
a key role in gluconeogenesis and increases blood glucose levels [45,46]. The deletion of FOXO-1 in
mice has been shown to normalise glucose tolerance [45,47,48]. In the current study, glucose intolerance
is increased substantially in HFD fed mice with several folds increase in FOXO-1. UTS-001 (6 mg)
treatment in HFD fed mice decrease FOXO-1 expression indicating the mechanism underlying improved
glucose tolerance also partially due to reduced liver gluconeogenesis. Furthermore, it has been shown
that PPARγ can directly regulate the genes responsible for lipid homeostasis [49]. In response to
HFD feeding, PPARγ is the early-induced lipogenic transcription factor in the liver [50,51]. FFA
treatment can cause up-regulation of PPARγ via PGC1α in liver cells, and both PGC1α and PPARγ
were elevated in the liver of mice with nonalcoholic fatty liver disease, a disease closely associated
with obesity and HFD consumption [52]. In agreement with the literature, in the current study, HFD
fed mice displayed several-fold increases in mRNA expression of liver PPARγ and PGC-1α in the face
of increased liver TG concentration. Although no significant effect was seen in PGC-1α after UTS-001
(6 mg) treatment, PPARγ was significantly reduced. An increase in expression of PPARγ is one of
the features of the steatotic liver and it is suggested that inhibiting the activity of PPARγ would be
beneficial in the prevention of steatosis [53] and improving glucose metabolism [52]. PPAR γ is a
likely target for small lipophilic compounds derived from endogenous metabolism and nutrition such
as phospholipids [54,55]. Therefore, modulating hepatic PPARγ as observed in this study might be
responsible for the improved glucose metabolism whilst preventing excessive liver steatosis.
IL-1β is a pro-inflammatory cytokine and is produced as an inactive protein. Biologically active
IL-1β is formed through caspase-1 activation via the NOD-, LRR- and pyrin domain-containing protein
3 (NLRP3) inflammasome [56]. This pathway has been suggested to contribute to the enhanced
inflammatory state, such as that observed in obesity and type 2 diabetes [57]. Furthermore, in adipose
tissue, activation of NLRP3 inflammasome results in inflammation and insulin resistance [58]. Growing
evidence suggests that IL-1βup-regulation contributes to the recruitment of adipose tissue macrophages
and induction of additional pro-inflammatory cytokines, contributing to impaired fat-liver crosstalk
thereby resulting in insulin resistance [59,60]. Although in this study IL-1β mRNA was not upregulated
in HFD-fed mice, UTS-001 suppressed IL-1β mRNA in the liver with a similar trend in the fat
suggesting additional anti-inflammatory properties of UTS-001. Therefore, the immunomodulatory
properties of UTS-001 cannot be attributed to a single pathway. Future studies will investigate the
TLR-4-MAPK/NF-KB pathway and NLRP3 inflammasome to further elucidate the full spectrum of
mechanisms of action for UTS-001.
Int. J. Mol. Sci. 2020, 21, 7640 13 of 20
GLUT2 is the most abundant isoform of glucose transporters in the liver which is responsible
for non-insulin stimulated glucose uptake [61]. Elevated hepatic GLUT2 can be observed following
HFD feeding [62] that can increase FFA synthesis blockage of the insulin receptor cascade and finally
insulin resistance [63]. Here, GLUT2 is upregulated in the liver in HFD-fed mice due to increased
blood glucose level, which is consistent with the literature. However, UTS-001 (6 mg) treatment did
not significantly downregulate GLUT2 mRNA expression, perhaps due to the need to process excess
sugar influx from the HFD. Interestingly, in the serum, FFA was somewhat reduced. Such change by
UTS-001 may also contribute to improved glucose clearance during IPGTT.
In this study, although we saw a small decrease in serum FFA level, TG levels in plasma were
not reduced by UTS-001 treatment. It has been demonstrated that lecithin, a natural PC, can reduce
lipid vacuoles in adipocyte by releasing TG, resulting in fat loss [64]. Hence, the synthetic PC in
UTS-001, DOPC, might have a similar effect on adipocytes. Upregulation of ATGL in HFD-UTS-001
(6 mg) in our study could indicate increased lipolysis, resulting in TG release from the fat tissue,
hence the unchanged in serum TG level and fat loss. PPARγ regulates fat cell differentiation which was
unchanged by UTS-001. Our in vitro study found fat cell size although not significant, was smaller in
the presence of high doses of UTS-001 although fat droplet number was not changed, suggesting the
role of increased lipolysis. CPT-1a is an enzyme that regulates the transportation of long-chain fatty acid
into the mitochondria for β-oxidation and has a crucial role in energy homeostasis [65]. The inhibition
of CPT-1a can improve insulin sensitivity in obese mice [66] and humans [67]. Unchanged liver CPT-1a
expression in HFD-UTS-001 (6 mg) may suggest that TG influx into the liver was not changed although
normalised CPT-1a level in the fat may suggest that the influx into the adipose tissue may be reduced
Further research is warranted to understand whether this dynamic will change in the longer term,
when fat mass is normalised to the control level.
UCP-1 is a thermogenic protein located in mitochondria of brown adipose tissue and there is
accumulating evidence that decreased expression of UCP-1 is linked to an increase in obesity and
vice-versa [68]. In the current study, we saw a marked increase in UCP-1 mRNA expression in
HFD-UTS-001 (6 mg) mice. Therefore, the increase in thermogenesis could be the other potential
mechanism for fat loss.
In addition to all the mechanisms discussed above, oleic acid, resulting from DOPC metabolism
in the body, has also been shown to reduce obesity in humans and demonstrate anti-inflammatory
properties [69,70]. Furthermore, choline, another product of DOPC metabolism can also promote
weight loss [71]. However, such effects of DOPC can only partially contribute to the overall effects of
UTS-001, as shown in our supplementary results of the DOPC-liposome. Other unknown metabolic
substrates from UTS-001 may play a role, which requires further investigation.
Liposomes are safe and biocompatible PC-based formulations and several liposomal formulations
have been approved as drug carriers by regulatory agencies. The liposomal formulation presented
in this study is an aqueous-based formulation. Several studies indicated the efficacy of nature PC
in reducing obesity. For instance, Lee et al. demonstrated the prophylactic administration of PC for
12 weeks in HFD fed mice alleviated HFD induced increases in body weight, mesenteric fat mass,
triglyceride and total cholesterol levels [17]. In the clinical practice, lecithin/DC injections (Lipostablil
or Lipodissolve) have been used locally to decrease fat deposits [72–74], attributed to the lysis of
adipose cells. However, such lysis is not cell-selective, thus LipoDissolve induces significant side
effects of inflammatory responses and neuronal damage [64,74–76]. Unlike previous studies, DOPC,
used in this study is a pure synthetic PC and DOPC-cholesterol liposomes (UTS-001) have shown
superior efficacy in body weight management and glycaemic control compared to the components of
formulation (DOPC and cholesterol mixture) (Supplementary Table S1 and Figure S1).
In conclusion, our findings demonstrate the strong efficacy of UTS-001 that can affect multiple
biological pathways involved in the development of obesity and related metabolic disorders and
represent a promising novel therapeutic strategy. Specific mechanisms behind improved glucose
update and anti-inflammatory properties will be further elucidated in future studies. Furthermore,
Int. J. Mol. Sci. 2020, 21, 7640 14 of 20
UTS-001 does not require further processing or functionalization to achieve its immunomodulatory
properties, hence facilitating its translation to the clinic. The results presented here support the
need for further investigation into the immunomodulatory properties of UTS-001 in other chronic
inflammatory conditions.
4. Materials and Methods
4.1. Animal Experiments
Liposomes were prepared as previously described [22]. The animal experiments were approved by
the Animal Care and Ethics Committee of the University of Technology Sydney (Ethics no: ETH18-2214,
Approved on 15/5/2018) and carried out according to the Australian National Health and Medical
Research Council Guide for the Care and Use of Laboratory Animals. Six-week-old C57BL/6 mice (male)
were purchased from the Animal Resource Centre, WA, Australia and were randomized into 6 groups
after a week of acclimatization. Chow group mice were fed a chow diet (12 KJ/g, 14% fat, Gordon’s
Specialty Stockfeeds, NSW, Australia) and HFD group mice were fed a high-fat diet (20 KJ/g, 43%
fat, Speciality feeds, Glen Forrest, WA, Australia) for 6 weeks. From the 7th week, an intraperitoneal
(i.p.) injection of either (1) PBS (vehicle control); (2) 0.6 mg UTS-001/day; or (3) 6 mg UTS-001/day,
was administered once daily for 4 weeks in HFD-fed mice with diet continuation (Figure 8). Body
weights and 24-h caloric-intake were monitored weekly. An intraperitoneal glucose tolerance test
(IPGTT) was conducted three days before the endpoint using our published method [77]. AUC was
calculated using 0.5 × (GlucoseT0 + GlucoseT15) × (15 − 0) + 0.5 × (GlucoseT15 + GlucoseT30) × (30 −
15) + 0.5 × (GlucoseT30 + GlucoseT60) × (60 − 30) + 0.5 × (GlucoseT60 + GlucoseT90) × (90 − 60). Fasting
blood glucose levels were measured at the endpoint using a hand-held glucose metre (Accu-Check®,
Roche Diagnostics GmbH, Sandhofer Strasse, Mannheim, Germany) and plasma was stored at −20 ◦C.
The heart, liver, spleen, kidneys, and fat pads were weighed. Liver and fat tissue were either fixed in
10% formalin or stored at −80◦C for further analysis. All analyses were performed blindly and the
results were only identified before data analysis.
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4.1.1. Bioassays 
Plasma non-esterified free fatty acids (NEFA) were measured using a NEFA kit (WAKO, Osaka, 
Japan). Liver TG was extracted by the Folch method using chloroform: methanol (2:1) mixture as 
previously described [78]. TG was measured in plasma by an in-house assay using glycerol standards 
(Sigma-Aldrich, St. Louis, MO, USA) and triglyceride reagent (Roche Diagnostics, Branchburg, NJ, USA) 
[79]. Plasma insulin levels were measured using a Mouse Insulin ELISA kit (Abnova, Taipei, Taiwan) 
following the manufacturer’s instructions. The Homeostatic Model Assessment of Insulin Resistance 
(HOMA-IR) was calculated according to the formula: insulin (μU/mL) × glucose (mM)/22.5. 
For oil red O staining, the oil red O working solution was prepared using 0.25% w/v oil red O 
stain (Sigma-Aldrich, Castle Hill, NSW, Australia) in isopropanol. Oil red O working solution was 
added to the frozen liver (30–40 mg) and homogenised. Samples were extracted with isopropanol. 
The optical density was measured at 520 nm and corrected by tissue weight. 
4.1.2. Immunohistochemistry 
Formalin-fixed liver and abdominal fat samples were embedded in paraffin and sectioned (5 
μm). The sections were then deparaffinized and rehydrated using xylene and decreasing grades of 
ethanol. Antigen retrieval was performed [80] before incubating with a rabbit anti-mouse F4/80 
(1:400, Abcam, Cambridge, UK), rabbit anti-mouse CD68 (1:300, Abcam, Cambridge, UK) primary 
antibodies. Horseradish peroxidase anti-rabbit Envision system (Dako Cytochemistry, Tokyo, Japan) 
was used to visualize. The sections were then counterstained with hematoxylin. Three images from 
each section were captured and used for analysis with ImageJ (National Institutes of Health, 
Bethesda, MD, USA). 
  
i r . c tic i r f i l ri ts.
4.1.1. Bioassays
Plas a non-esterified free fatty acids (NEFA) ere easured using a NEFA kit ( AKO, Osaka,
Japan). Liver TG as extracted by the Folch ethod using chlorofor : ethanol (2:1) ixture as
previously described [78]. TG was easured in plas a by an in-house assay using glycerol standards
(Sig a-Aldrich, St. Louis, MO, USA) and triglyceride reagent (Roche Diagnostics, Branchburg, NJ,
USA) [79]. Plasma insulin levels were measured using a Mouse Insulin ELISA kit (Abnova, Taipei,
Taiwan) following the manufacturer’s instructions. The Homeostatic Model Assessment of Insulin
Resistance (HOMA-IR) was calculated according to the formula: insulin (µU/mL) × glucose (mM)/22.5.
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For oil red O staining, the oil red O working solution was prepared using 0.25% w/v oil red O
stain (Sigma-Aldrich, Castle Hill, NSW, Australia) in isopropanol. Oil red O working solution was
added to the frozen liver (30–40 mg) and homogenised. Samples were extracted with isopropanol.
The optical density was measured at 520 nm and corrected by tissue weight.
4.1.2. Immunohistochemistry
Formalin-fixed liver and abdominal fat samples were embedded in paraffin and sectioned
(5 µm). The sections were then deparaffinized and rehydrated using xylene and decreasing grades of
ethanol. Antigen retrieval was performed [80] before incubating with a rabbit anti-mouse F4/80 (1:400,
Abcam, Cambridge, UK), rabbit anti-mouse CD68 (1:300, Abcam, Cambridge, UK) primary antibodies.
Horseradish peroxidase anti-rabbit Envision system (Dako Cytochemistry, Tokyo, Japan) was used to
visualize. The sections were then counterstained with hematoxylin. Three images from each section
were captured and used for analysis with ImageJ (National Institutes of Health, Bethesda, MD, USA).
4.1.3. Quantitative Real-Time PCR
Total RNA was isolated from the tissues using Trizol reagent (Sigma-Aldrich, St. Louis, MO,
USA). First-strand cDNA was synthesized using M-MLV Reverse Transcriptase, RNase H Minus,
Point Mutant Kit (Promega, Fitchburg, WI, USA). Pre-optimized TaqMan® probe/primer and SYBR
green expression assays primers (information in Supplementary Tables S2 and S3, Life Technologies,
Carlsbad, CA, USA) were used for the real-time PCR (Eppendorf Realplex2, Hamburg, Germany).
The genes of interest were normalised against the 18s rRNA. The average value of the Chow-PBS was
set as the calibrator, against which all other samples are expressed as a fold difference.
4.2. Cell Culture Studies and Cellular 2-NBDG Uptake
The Murine 3T3-L1 fibroblasts were purchased from Cell bank Australia, NSW, Australia and
were maintained at 5% CO2 and 37 ◦C. Murine 3T3-L1 fibroblasts were differentiated into mature
adipocytes using a previously published protocol [81,82].
To measure the uptake of glucose into adipocytes, 2-NBDG uptake was used. Mature adipocytes
were pretreated with PBS, Metformin (1 µM), or UTS-001 (0.375, 1.125, 2.25, 3.375 mg of lipids/mL)
in high glucose DMEM for 24 h. Following incubation, the adipocytes were washed with PBS and
serum-starved for 3 h using 0.1% BSA in glucose-free phenol red free DMEM. Adipocytes were then
incubated with 160 µM of 2-NBDG (2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose)
and insulin (100 nM) for 60 min in serum and glucose-free DMEM. The 2-NBDG uptake was ceased by
washing the cells with precooled PBS. The fluorescence was measured by a Tecan microplate reader at
an excitation wavelength of 485 nm and an emission wavelength of 535 nm.
In order to measure the diameter of the lipid droplets following the treatment with UTS-001, Oil
Red O staining was used. In brief, on day 8, mature adipocytes were treated with PBS, or UTS-001
(0.375, 1.125, 2.25, 3.375 mg of lipids/mL) for 48 h. Following incubation, the adipocytes were washed
with PBS and then fixed with 4% ice cold paraformaldehyde for 30 min followed by washing with 60%
isopropyl alcohol. Fixed cells were then stained with 0.1% Oil Red O working solution for 15 min and
then rinsed with milli-Q water. Dapi (300 nM) was used to counterstain the cells. The cells were imaged
with IN Cell Analyser 2,200 (GE Healthcare, Issaquah, WA, USA) and the images were analysed by
ImageJ software.
4.3. Statistical Analysis
Data are represented as mean ± S.E.M. Data were analyzed using two-way ANOVA, followed
by post hoc uncorrected Fisher’s LSD tests if the data is normally distributed. If the data were not
normally distributed, they were log-transformed to achieve normality of distribution before analysis.
(Graphpad Prism software, San Diego, CA, USA). For in vitro studies and HFD-fed mice treated with
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individual components, data were analyzed using one-way ANOVA, followed by post hoc uncorrected
Fisher’s LSD tests.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/20/
7640/s1.
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FASN Fatty acid synthase
SREBP-1c Sterol regulatory element-binding protein 1
MCP-1 Monocyte chemoattractant protein-1
FOXO-1 Forkhead box protein O1
ATGL Adipose triglyceride lipase
TNF-α Tumor necrosis factor-alpha
UCP-1 Uncoupling protein-1
UCP-3 Uncoupling protein-3
PPARγ Peroxisome Proliferator Activated Receptor Gamma
TLR4 Toll-like receptor-4
CPT1a Carnitine palmitoyltransferase 1a
PGC1 α Peroxisome proliferator-activated receptor gamma coactivator 1-α
GLUT 2 Glucose transporter 2
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine
NLRP3 NOD-, LRR- and pyrin domain-containing protein 3
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